Sei Investments Co. Boosts Stock Position in BioLife Solutions, Inc. (NASDAQ:BLFS)

Sei Investments Co. boosted its position in BioLife Solutions, Inc. (NASDAQ:BLFS) by 100.1% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 120,418 shares of the medical equipment provider’s stock after buying an additional 60,227 shares during the quarter. Sei Investments Co. owned approximately 0.26% of BioLife Solutions worth $2,581,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also bought and sold shares of BLFS. 1620 Investment Advisors Inc. purchased a new position in BioLife Solutions in the 2nd quarter worth approximately $35,000. Isthmus Partners LLC lifted its position in shares of BioLife Solutions by 34.4% in the 2nd quarter. Isthmus Partners LLC now owns 165,247 shares of the medical equipment provider’s stock worth $35,000 after purchasing an additional 42,265 shares during the period. Register Financial Advisors LLC bought a new stake in shares of BioLife Solutions during the 1st quarter valued at about $96,000. Canada Pension Plan Investment Board purchased a new position in shares of BioLife Solutions during the second quarter valued at about $122,000. Finally, Arizona State Retirement System bought a new position in shares of BioLife Solutions in the 2nd quarter worth approximately $217,000. 93.24% of the stock is currently owned by institutional investors.

Insider Activity at BioLife Solutions

In other BioLife Solutions news, CRO Garrie Richardson sold 3,070 shares of BioLife Solutions stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $25.12, for a total transaction of $77,118.40. Following the completion of the sale, the executive now directly owns 114,773 shares in the company, valued at $2,883,097.76. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, CRO Garrie Richardson sold 3,070 shares of the business’s stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $25.12, for a total transaction of $77,118.40. Following the completion of the transaction, the executive now directly owns 114,773 shares of the company’s stock, valued at approximately $2,883,097.76. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Aby J. Mathew sold 10,000 shares of the stock in a transaction that occurred on Wednesday, September 18th. The shares were sold at an average price of $23.90, for a total value of $239,000.00. Following the completion of the sale, the executive vice president now directly owns 317,716 shares of the company’s stock, valued at $7,593,412.40. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 16,944 shares of company stock valued at $405,619. 2.20% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

BLFS has been the topic of a number of recent research reports. TD Cowen upped their target price on shares of BioLife Solutions from $20.00 to $26.00 and gave the stock a “buy” rating in a research report on Wednesday, July 17th. HC Wainwright started coverage on BioLife Solutions in a research note on Monday, September 30th. They issued a “buy” rating and a $29.00 target price on the stock. Craig Hallum raised their price objective on shares of BioLife Solutions from $23.00 to $30.00 and gave the company a “buy” rating in a research note on Monday, August 12th. Finally, Northland Securities lifted their target price on BioLife Solutions from $26.00 to $28.00 and gave the stock an “outperform” rating in a report on Friday, August 9th. One analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, BioLife Solutions currently has an average rating of “Moderate Buy” and a consensus target price of $26.67.

BioLife Solutions Stock Up 0.9 %

NASDAQ:BLFS opened at $24.54 on Friday. The company’s 50-day simple moving average is $24.60 and its 200-day simple moving average is $21.36. BioLife Solutions, Inc. has a fifty-two week low of $8.92 and a fifty-two week high of $26.73. The stock has a market capitalization of $1.13 billion, a P/E ratio of -17.28 and a beta of 1.88. The company has a debt-to-equity ratio of 0.04, a quick ratio of 1.81 and a current ratio of 2.86.

BioLife Solutions (NASDAQ:BLFS) last announced its quarterly earnings results on Thursday, August 8th. The medical equipment provider reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.08. BioLife Solutions had a negative return on equity of 10.75% and a negative net margin of 59.88%. The company had revenue of $28.33 million for the quarter, compared to the consensus estimate of $23.80 million. On average, equities analysts anticipate that BioLife Solutions, Inc. will post -0.36 earnings per share for the current fiscal year.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.